Syndax(SNDX) - 2024 Q4 - Annual Results

Exhibit 99.1 Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update • $7.7 million in Revuforj ® (revumenib) net product revenue in initial five weeks of launch – approximately one-third of the net revenue represents inventory at specialty pharmacies and specialty distributors and the remainder represents patient demand. Revuforj was launched in the U.S. in late November 2024, following the FDA's approval on November 15, 2024 for the treatment of relapsed or refracto ...